Fact-checked by Grok 2 weeks ago

Electronic data capture

data capture () is a of systematically capturing, reviewing, managing, storing, analyzing, and reporting clinical investigation data using computerized systems, where source data is initially recorded in digital format and entered into an (eCRF) for submission to sponsors in accordance with the study protocol. Primarily utilized in human clinical trials across all phases, EDC automates , validation, query resolution, and , enabling direct entry into centralized databases while replacing traditional paper-based processes. EDC systems emerged in the late 1990s as web-based technologies advanced, with adoption accelerating in the early 2000s due to regulatory support and the need for efficient data handling in complex trials; by the mid-2000s, approximately 40% of phase II-IV trials in surveyed regions employed , and usage has since become nearly ubiquitous, with nearly 80% of clinical trials incorporating these systems by 2023. Key features include real-time data access, built-in logic checks to flag discrepancies during entry, audit trails for , and integration with electronic health records (EHRs) for streamlined source data verification. The primary advantages of EDC include enhanced data accuracy and completeness by minimizing transcription errors and duplication, faster trial timelines through remote monitoring and immediate query resolution, and improved via adherence to standards like 21 CFR Part 11 for electronic records and signatures. However, challenges persist, such as high implementation costs for smaller or academic trials, potential system failures, and the need for user training to ensure . Recent advancements, including AI-driven and compatibility with decentralized trial models, continue to expand EDC's role in fostering efficient, patient-centric research.

Introduction

Definition and Scope

Electronic data capture (EDC) refers to a computerized system designed for the collection, management, and storage of clinical and research data in electronic format, primarily replacing traditional paper-based case report forms (CRFs). This approach enables the direct entry of data into electronic case report forms (eCRFs) through digital interfaces, facilitating automated validation, audit trails, and compliance with regulatory standards such as FDA's 21 CFR Part 11. The scope of EDC encompasses human clinical trials across all phases (I-IV), with primary utilization in later phases (II-IV), as well as pharmacovigilance activities and post-market surveillance efforts within the pharmaceutical, , and industries. These systems support the capture of source data from diverse origins, including electronic health records (EHRs) and direct site inputs, to ensure , , and reliability for regulatory submissions and . In contrast to paper-based data capture, which relies on manual transcription and physical handling prone to errors and delays, EDC employs web-based or mobile applications for entry by site personnel, allowing immediate centralized storage in secure databases. The basic involves site staff inputting via user-friendly forms, followed by automated query generation for discrepancies and resolution processes that occur electronically without the need for physical document exchange, thereby streamlining overall .

Role in Clinical Research

Electronic data capture (EDC) plays a pivotal role in accelerating drug and development within by streamlining processes and enhancing overall efficiency. By enabling entry and automated validation, EDC significantly reduces the time required for data gathering and processing, often shortening timelines from months to days for key activities such as query resolution and initial data availability. This acceleration is particularly evident in the minimization of manual handling, which traditionally delays workflows in paper-based systems. Furthermore, EDC improves data accuracy by incorporating built-in checks that detect inconsistencies at the point of entry, leading to up to a 99% reduction in transcription errors compared to manual methods. In clinical trial phases, EDC is primarily utilized in later-stage studies (Phases II-IV), with increasing adoption in early-phase studies including Phase I, where large-scale data volumes demand robust management to support efficacy and safety evaluations. Adoption rates in Phases II-IV reached approximately 41% among Canadian trials in the mid-2000s, with higher usage in industry-sponsored efforts involving complex datasets and having become nearly ubiquitous by the 2020s. Beyond confirmatory trials, EDC facilitates real-world evidence collection in post-approval settings, such as Phase IV surveillance, by integrating diverse data sources for ongoing monitoring of drug performance in broader populations. The broader impacts of EDC extend to enabling faster regulatory submissions through cleaner, audit-ready datasets that expedite review processes by regulatory bodies. It also delivers cost savings, with estimates indicating a 9.8% reduction in total trial costs and up to 20-30% decreases in expenses due to diminished needs for handling, , and correction. These efficiencies contribute to improved patient outcomes by providing timely insights into treatment effects, allowing for quicker adjustments in trial protocols or post-market strategies. Successful implementation of EDC requires trained personnel familiar with digital interfaces and compatible , such as reliable and , to ensure seamless adoption without disrupting operations. These prerequisites highlight the need for organizational in setup to fully realize EDC's potential in the ecosystem.

Historical Development

Origins in Remote Data Entry

Remote data entry (RDE), a precursor to modern electronic data capture (EDC), began in the 1970s and gained traction in the late 1980s as software enabling clinical trial sites to input data directly into centralized systems using modems, thereby eliminating the need to mail physical paper forms. Early precursors to RDE appeared in the 1970s, such as the NIH-sponsored Kidney Transplant Histocompatibility Study in 1973, which piloted remote terminals at select sites. This approach represented an initial shift from traditional paper-based methods, where data were manually transcribed after shipment, often leading to prolonged processing times. Early RDE systems leveraged portable computers connected via dial-up telephone lines to transmit case report forms (CRFs) in real time or near-real time to coordinating centers. A notable implementation occurred in 1989 with the Hypertension Prevention Trial, a multicenter study that utilized a distributed system for and data monitoring across four clinics and resource centers. In this trial, the system facilitated direct entry of patient data at sites, supporting the evaluation of dietary interventions on . This application highlighted RDE's potential for multicenter coordination, though adoption remained limited to select studies due to its novelty. Initial RDE systems were predominantly thick-client applications, requiring on-site hardware installations and specialized software at each trial site, which posed significant logistical challenges. relied on unreliable dial-up modems, contributing to sporadic usage as high setup costs, training demands, and technical support needs deterred widespread implementation. These barriers restricted RDE to trials with substantial sponsor resources, often resulting in inconsistent data transmission and integration issues. The development of RDE was driven by increasing awareness of paper-based data collection's inefficiencies in the 1980s landscape, including illegible handwriting that caused transcription errors and substantial delays from shipping and double-key entry processes. These problems, which could extend data availability by months, underscored the need for more efficient alternatives to support timely analysis and decision-making in growing trial portfolios.

Evolution to Modern Systems

The proliferation of the in the mid-1990s facilitated a pivotal shift in electronic data capture () systems for s, transitioning from standalone remote (RDE) tools to web-based platforms that allowed direct access without the need for specialized client software. This evolution enabled decentralized input from multiple trial sites while centralizing storage and processing on remote servers, marking a departure from the localized, site-specific entry methods of earlier RDE systems that relied on lines or floppy disks for . One of the earliest commercial web-based EDC systems, Medidata's , launched in June 1999, exemplified this advancement by providing a secure, internet-accessible interface for capturing and managing in real time. A key regulatory milestone supporting this transition was the U.S. Food and Drug Administration's (FDA) April 1999 guidance on "Computerized Systems Used in Clinical Trials," which established requirements for the integrity, auditability, and validation of electronic records and signatures under 21 CFR Part 11, thereby legitimizing web-based EDC for regulatory submissions. Widespread adoption accelerated after 2000, coinciding with improvements in broadband infrastructure that enhanced data transmission speeds and reliability, allowing for more efficient handling of large-scale, multi-site trials. By 2004, approximately 70% of clinical trial sites were utilizing EDC systems, reflecting a growing industry consensus on their feasibility. The move to centralized servers addressed longstanding issues of data silos inherent in site-based RDE, where disparate local systems often led to inconsistencies and delays in aggregation, but it introduced new challenges such as the need for standardized data formats and protocols to ensure across global trial networks. Early adopters faced hurdles including immature software reliability, extensive training requirements for site personnel, and organizational resistance to changes, which slowed initial uptake to just 5% of new trials by 2001. These transitions were further complicated by the variability in data definitions and handling practices among sites, necessitating emerging standards like those from the Clinical Data Interchange Standards Consortium (CDISC), formed in 1999. By the early 2000s, web-based platforms began incorporating basic validation rules, such as univariate and multivariate edit checks, to automatically detect discrepancies during and reduce query volumes by up to 82% compared to manual processes. This integration of real-time validation marked a significant step toward scalable, multi-site trials, improving accuracy and enabling faster of issues without extensive post-entry cleaning.

Technical Components

Core System Features

Contemporary electronic data capture (EDC) systems are built around components that facilitate efficient and secure in clinical trials. Central to these interfaces are customizable electronic case report forms (eCRFs), which allow sponsors to design tailored digital questionnaires using drag-and-drop builders or point-and-click tools to capture protocol-specific patient data without requiring extensive programming. Role-based access controls (RBAC) are integral, assigning permissions based on user roles—such as investigators who can enter and edit site data, monitors who review for discrepancies, and sponsors who oversee overall access—ensuring that only authorized personnel interact with sensitive information. trails, mandated for , automatically log all actions including data creation, modifications, and deletions with timestamps and user identifiers, supporting as required under 21 CFR Part 11. The backend infrastructure of EDC platforms emphasizes scalability and reliability through cloud-based storage solutions, which enable distributed access across global trial sites while handling large volumes of data without on-premises hardware demands. Real-time data validation occurs via automated edit checks, such as range validations, logical consistency rules, and cross-field queries, that flag inconsistencies immediately upon entry to prevent errors from propagating. Supporting tools within EDC systems include query management modules that automate the generation, assignment, and resolution of data discrepancies, allowing sites to respond directly within the platform to streamline communication and reduce resolution times. dashboards provide configurable visualizations of key metrics, such as enrollment progress and data completeness, enabling interim analyses and oversight without exporting data. Security measures in EDC platforms incorporate robust standards, including AES-256 for and TLS for , to protect against unauthorized access and breaches. signatures, compliant with 21 CFR Part 11, verify and intent for critical actions like data approvals, ensuring the integrity and of records.

Data Collection and Management Processes

Electronic data capture (EDC) systems in clinical trials follow a structured lifecycle that begins with the design of electronic case report forms (eCRFs), which are configured to align with the study protocol and capture only essential elements. This phase involves collaboration among end-users, such as site staff and data managers, to ensure and incorporate built-in validation rules for checks. Once designed, eCRFs serve as the primary interface for throughout the trial, progressing through collection, management, cleaning, and culminating in database lock and archiving to preserve for long-term accessibility. Data collection in EDC systems primarily occurs through direct entry using web-based or mobile forms, where investigators or site personnel input subject visit data into centralized databases via secure, user-specific accounts. For automated capture, systems integrate with electronic health records (EHRs) to enable seamless transfer of variables such as demographics, lab values, and comorbidities, often processed overnight to minimize manual intervention; these integrations commonly utilize standards like HL7 FHIR for interoperability. Similarly, integration with wearables or other devices allows real-time ingestion of physiological data, such as heart rate or activity metrics, with metadata like timestamps to maintain traceability. Following collection, management processes emphasize data cleaning through automated edit checks that flag inconsistencies, out-of-range values, or missing entries during entry, generating queries for resolution. Data is often structured according to CDISC standards to facilitate analysis and regulatory submission. These queries are routed to investigators for review and correction, with all changes tracked via audit trails to document who made modifications and when. Once cleaned, datasets are locked to prevent further alterations, enabling export in formats compatible with statistical software like for analysis. Quality assurance protocols in EDC workflows include double-data entry verification for transcribed data from paper sources, where two independent entries are compared to identify discrepancies, reducing errors compared to single entry. Discrepancy resolution follows standardized procedures, such as flagging issues in the system, notifying clinical monitors, and requiring sign-off within set timelines to ensure timely corrections. These measures uphold + principles—ensuring data is attributable, legible, contemporaneous, original, accurate, complete, consistent, enduring, and available—throughout the process.

Benefits and Challenges

Key Advantages

Electronic data capture (EDC) systems significantly improve in clinical trials by implementing validation rules and logic checks that flag inconsistencies during entry, thereby minimizing transcription errors and issues related to illegible common in paper-based methods. Studies have demonstrated substantial error reductions, with one of a multi-site trial reporting an 86% decrease in the number of data queries compared to traditional approaches. This enhanced accuracy ensures more reliable datasets for , reducing the need for post-collection corrections. EDC offers notable efficiency gains, shortening overall study timelines through immediate data availability and remote monitoring capabilities that accelerate decision-making and query resolution. For instance, indicates that EDC can reduce durations by approximately 20-30%, with specific cases showing up to 43% faster database lock times. These improvements translate to cost savings, particularly in later phases; a Forrester Research estimated potential reductions of up to $6.25 million in a Phase III trial involving 200 sites and 2,000 subjects, driven by decreased manual handling and monitoring visits. The systems enhance among global stakeholders by providing secure, access to , enabling coordinated efforts across sites and faster of discrepancies without physical data transfers. This supports adaptive designs where interim analyses can inform ongoing adjustments, fostering better integration between sponsors, contract research organizations, and investigators. Finally, excels in , managing large volumes of data from diverse sources such as electronic health records and patient-reported outcomes, which facilitates advanced analytics and integration with tools for deeper insights into trial outcomes. Cloud-based platforms further allow seamless expansion to accommodate multi-site, studies without proportional increases in infrastructure demands.

Limitations and Implementation Barriers

Electronic data capture (EDC) systems, while offering efficiency in clinical trials, face significant technical barriers that can hinder widespread adoption. High initial setup costs, which can range from $50,000 to over $200,000 for and in mid-sized trials depending on complexity and vendor, pose a substantial financial challenge, particularly for smaller organizations or academic institutions with limited budgets. Additionally, EDC's reliance on stable internet connectivity creates vulnerabilities in remote or resource-limited settings, where unreliable access can delay data entry and increase error rates during site visits. User adoption remains a critical obstacle, driven by the need for extensive among non-technical such as clinical coordinators and investigators. In many cases, personnel accustomed to paper-based methods exhibit , with earlier surveys indicating significant opposition in emerging markets to real-time data entry due to perceived disruptions and discomfort using systems in front of patients. This is compounded by the demands of learning new interfaces, further slowing trial progress without adequate support. Beyond human factors, while earlier EDC systems exhibited limited flexibility for complex, non-standardized protocols, such as adaptive trials requiring mid-study amendments, which often necessitated system for updates and risked incomplete data capture if changes were not seamlessly communicated, modern systems support these updates without interruption. Risks of system from technical glitches or further exacerbate delays, while cyber threats—including and attacks targeting sensitive patient data—introduce security vulnerabilities that demand constant vigilance. To address these barriers, strategies such as phased rollouts—starting with pilot sites to refine processes—and the development of user-friendly interfaces with minimalistic designs have been employed to ease and reduce burdens. More recent approaches as of 2024 include AI-driven for intuitive and enhanced with electronic health records to further mitigate challenges. As of 2025, EDC adoption has become nearly ubiquitous in phase II-IV clinical trials, with ongoing challenges primarily focusing on data standardization across global sites and cybersecurity in decentralized trial models that incorporate wearables and remote monitoring.

Regulatory and Standards Framework

Major Guidelines and Regulations

The U.S. Food and Drug Administration's (FDA) 21 CFR Part 11, originally promulgated in 1997 and with guidance updated in 2003, establishes the criteria under which electronic records and electronic signatures are considered trustworthy, reliable, and equivalent to paper records and handwritten signatures. This regulation applies to FDA-regulated industries, including clinical research, and mandates requirements such as system validation to ensure accuracy, reliability, and consistent performance; secure controls to limit access to authorized individuals; audit trails to record actions on records; and operational checks to enforce sequence and integrity of data entry. In October 2024, the FDA finalized a Q&A guidance on "Electronic Systems, Electronic Records, and Electronic Signatures in Clinical Investigations," clarifying the application of Part 11 to modern clinical trials, including electronic data capture (EDC) systems, real-world data sources, and digital health technologies. It specifies that FDA assesses Part 11 compliance once electronic records are entered into a sponsor's EDC system, emphasizing data integrity, secure transmission, and validation for electronic signatures in informed consent and trial documentation. The International Council for Harmonisation's (ICH) (R3) guideline, adopted in 2025 as a revision to the (GCP) standard (previously updated as R2 in 2016), provides an international ethical and scientific quality framework for clinical trials, with expanded provisions for . It requires sponsors to ensure that electronic systems conform to standards for , completeness, accuracy, and reliability, including risk-based monitoring, validation of systems for secure handling (such as and secure storage), to prevent unauthorized access or alterations, and maintenance of audit trails. The R3 update reflects advancements in digital technologies, supporting decentralized trials and enhanced . In the European Union, the European Medicines Agency's (EMA) Annex 11 to the Good Manufacturing Practice (GMP) guidelines, originally effective in 2011 and revised in 2025, serves as the counterpart to 21 CFR Part 11 and outlines principles for the use of computerized systems in the manufacture and control of medicinal products, including clinical trials. The 2025 revision adopts a more prescriptive risk-based approach to validation, requiring comprehensive system lifecycle management, enhanced data integrity measures (including for data in motion and at rest), audit trails, access controls, personnel training, and specific guidance on emerging technologies such as AI/machine learning, cloud services, and cybersecurity to mitigate risks in electronic data capture and processing. For global harmonization in electronic data capture, the Clinical Data Interchange Standards Consortium (CDISC) develops and maintains standards such as the Study Data Tabulation Model (SDTM) and Clinical Data Acquisition Standards Harmonization (CDASH), which facilitate interoperable data exchange across systems and jurisdictions in . These standards ensure consistent data structure and formatting, enabling efficient submission to regulatory authorities like the FDA and while supporting seamless integration and analysis of electronic data from diverse sources.

Compliance and Validation Requirements

Electronic data capture (EDC) systems require rigorous validation to ensure reliability and compliance with regulatory expectations for in clinical trials. The validation process typically involves three key phases: Installation Qualification (IQ), which verifies that the system is installed correctly according to specifications and documentation; Operational Qualification (OQ), which tests the system's functionality under normal operating conditions to confirm it performs as intended; and Performance Qualification (PQ), which evaluates the system's performance in a simulated or actual production environment to ensure consistent and reliable operation over time. These phases collectively demonstrate that the EDC system can accurately capture, store, and retrieve data without errors or unauthorized alterations, providing assurance to sponsors and regulators. Maintaining ongoing compliance in EDC systems demands structured procedures to preserve throughout the system's lifecycle. Change control procedures outline the steps for evaluating, approving, and documenting any modifications to the system, such as software updates or changes, to prevent unintended impacts on . Periodic audits involve regular reviews of system performance, data handling, and adherence to protocols, often conducted by internal quality teams or external inspectors to identify and rectify potential issues. User access logging is essential, capturing detailed records of who accessed the system, when, and what actions were taken, enabling traceability and detection of any unauthorized activities. Risk management in EDC validation follows established guidelines like GAMP 5 (2nd edition, 2022), which promotes a risk-based approach to categorize software according to its potential impact on , product quality, and . Under GAMP 5, EDC systems are typically classified into categories such as Category 4 (configurable software) or Category 5 (), allowing organizations to tailor validation efforts proportionally to the identified risks, focusing resources on high-impact areas while streamlining lower-risk components. This methodology integrates quality risk management principles to assess threats like or system failures, ensuring validation is efficient yet comprehensive. Comprehensive documentation supports compliance through standardized operating procedures (SOPs) that govern critical functions in systems. SOPs for data backup specify routines for regular, automated backups to secure off-site storage, including verification of backup integrity to prevent data loss. SOPs detail step-by-step responses to system disruptions, such as protocols and restoration timelines, to minimize and ensure business continuity. Additionally, SOPs for submission-ready exports require generating data in formats like the (), which standardizes data for regulatory submissions while maintaining audit trails and metadata.

Current Landscape

As of 2023, electronic data capture (EDC) systems have achieved widespread adoption in clinical trials, with nearly 80% of studies utilizing these platforms for data collection, a substantial increase from approximately 40% in the late 2000s. This growth reflects a shift from paper-based methods, accelerated by the COVID-19 pandemic, which promoted decentralized trial models requiring remote and real-time data management to maintain trial continuity amid site closures and travel restrictions. In 2025, industry reports such as Veeva's Clinical Data Trend Report emphasize the rise of risk-based monitoring and a focus on practical AI applications in EDC. Usage patterns show EDC dominance in later-stage trials, particularly Phase III, where it accounts for more than 50% of capture activities due to the complexity and volume of involved. Adoption is also expanding in (RWE) studies, facilitated by mobile-enabled EDC platforms that support patient-reported outcomes and direct entry from diverse sources outside traditional clinical settings. Key trends include a pronounced shift toward software-as-a-service (SaaS) models, which provide scalability and rapid deployment, dominating the market for web- and cloud-based EDC solutions. Integration with (AI) for predictive data queries and has further streamlined processes, contributing to reductions in overall trial timelines by minimizing manual data reviews and errors. North America holds the largest market share at approximately 49% as of 2024, followed by , together dominating the global EDC market through advanced and regulatory support. In contrast, exhibits emerging growth at a faster pace, driven by expanding healthcare investments and outsourcing, though penetration lags behind developed regions due to varying digital .

Major Providers and Market Dynamics

The electronic data capture (EDC) market in 2025 is valued at approximately USD 1.86 billion, with projections indicating growth to USD 3.28 billion by 2030 at a of 12.02%, driven by increasing demand for efficient data and regulatory compliance. This expansion reflects broader adoption in pharmaceutical and sectors, where EDC systems streamline and reduce errors compared to paper-based methods. Leading providers dominate the landscape, with ' Rave EDC platform recognized as the top choice by nearly half of clinical trial sponsors and contract research organizations (CROs) in a 2025 industry survey, underscoring its market leadership in handling complex, large-scale trials. 's InForm EDC, positioned as a leader in the 2024 PEAK Matrix assessment, excels in scalability and compliance for global studies, integrating seamlessly with broader life sciences suites. ' Vault EDC complements this trio by offering a unified for data capture and review, having surpassed 1,000 study starts in 2024 and emphasizing user-friendly interfaces for faster study builds. Together, these major vendors—Medidata, Oracle, and Veeva—command a substantial portion of the market, estimated at over 50% based on user preference and deployment metrics from recent analyst reports. Open-source alternatives like OpenClinica provide cost-effective options for smaller organizations, supporting electronic case report forms (eCRFs) and without licensing fees, though they require in-house technical expertise for customization. Market dynamics are shaped by strategic mergers and competitive pressures, notably ' 2019 acquisition of Medidata for USD 5.8 billion, which enhanced its virtual twin experiences in healthcare and bolstered Medidata's cloud-based capabilities. intensifies around integration with electronic health records (EHRs), where solutions like 's EMR-to-EDC automate data transfer to improve trial efficiency and generation. Pricing models vary, with subscription-based dominating (e.g., Veeva and Oracle's cloud offerings) for predictable costs and scalability, while legacy perpetual licenses persist in some enterprise setups but are declining amid shifts to flexible, pay-per-use structures. The EHR-to-EDC integration segment alone is growing at a 13.8% CAGR through 2033, highlighting how drives vendor differentiation. Niche players cater to specific scales, such as EDC, which targets academic and small-to-mid-sized trials with its intuitive, cloud-based interface and low setup costs, enabling rapid deployment for studies under 500 patients. In contrast, focuses on enterprise-level solutions, providing comprehensive EDC within its orchestrated clinical trials ecosystem for multinational pharma, emphasizing data analytics and global compliance. These dynamics foster innovation while consolidating power among top providers, aligning with rising adoption trends in decentralized trials.

Future Directions

Emerging Technologies and Innovations

The integration of (AI) and (ML) into electronic data capture (EDC) systems is revolutionizing data management by automating complex processes that traditionally required manual intervention. AI-driven tools now perform automated data reconciliation by cross-verifying entries from multiple sources, such as electronic health records and laboratory results, reducing discrepancies. Similarly, ML algorithms enable real-time , flagging outliers like inconsistent or protocol deviations with high precision, which minimizes false positives and supports proactive query resolution, potentially accelerating database lock timelines by 30-50%. For instance, models forecast patient enrollment dropouts by analyzing behavioral patterns and engagement metrics, allowing sponsors to intervene early and improve retention rates, where dropouts affect 25-30% of participants due to factors like motivation loss. Blockchain technology is emerging as a robust solution for enhancing in platforms, particularly in multi-site clinical trials where and are paramount. By creating immutable audit trails, ensures that every data entry, modification, or access event is permanently recorded in a decentralized , preventing tampering and providing verifiable across global sites. This approach not only complies with stringent regulatory requirements for but also fosters among stakeholders by allowing secure, permissioned without compromising . In practice, blockchain-integrated systems have demonstrated potential to streamline audits, reducing verification times while enhancing overall trial reliability. Advancements in mobile technologies and (IoT) devices are enabling seamless data streaming from wearables directly into EDC systems, facilitating continuous patient monitoring in decentralized trials. Wearable sensors, such as smartwatches tracking and activity, transmit real-time physiological data via secure to EDC platforms, eliminating manual transcription errors and supporting remote, longitudinal assessments. This integration allows for dynamic adjustments in trial protocols based on live metrics, enhancing safety and efficacy evaluations without frequent site visits. For example, -enabled home health devices now feed biometric streams into EDC databases, enabling 24/7 oversight that correlates digital biomarkers with clinical endpoints. Electronic patient-reported outcomes () have advanced significantly through mobile applications that capture subjective health data directly from participants, integrated seamlessly with for unified analysis. These apps employ user-friendly interfaces to collect daily symptom logs and quality-of-life measures, improving compliance through reminders and , which has led to higher response rates compared to paper-based methods. A key innovation includes geolocation validation features, such as IP-based restrictions or GPS confirmation, to verify participant location during reporting, ensuring data authenticity and preventing unauthorized submissions in global trials. This enhances the reliability of ePRO data, supporting regulatory acceptance and patient-centric trial designs.

Predicted Developments and Integrations

The expansion of eSource technologies is expected to transform electronic data capture () by 2030, with the U.S. Food and Drug Administration (FDA) actively promoting direct data capture from electronic health records (EHRs) and wearables to enable , remote acquisition in clinical trials. This guidance emphasizes validation of digital health technologies for accuracy and , positioning eSource as a core component of decentralized investigations and potentially diminishing the role of standalone systems by eliminating redundant data entry and transcription errors. Industry projections indicate the eSource and electronic clinical outcome assessment (eCOA) market will grow at a (CAGR) of 8.3% through 2030, driven by integrations that enhance data quality and trial speed. In the realm of decentralized clinical trials, platforms are forecasted to function as central hubs within virtual ecosystems, orchestrating integrations with services for remote patient interactions and AI-driven adaptive designs that allow real-time protocol modifications based on emerging data patterns. These advancements will support patient-centric models by combining wearable-derived metrics with consultations, reducing site dependencies and improving inclusivity, with the decentralized trials market projected to expand from USD 9.7 billion in 2025 to USD 29.7 billion by 2034 at a CAGR of 13.3%. Future predictions highlight near-universal integration of advanced in large-scale trials by the early 2030s, building on current trends where over 61% of sites already employ eSource systems. Sustainability efforts will increasingly incorporate green to minimize the of data storage and processing, as decentralized approaches have demonstrated potential to reduce emissions through reduced travel and paper use. Global equity in access will be prioritized via scalable, low-cost digital platforms that extend capabilities to underrepresented regions, fostering diverse trial participation and addressing disparities in . Persistent challenges will center on ethical AI deployment within EDC and data privacy in federated learning frameworks, where models train across institutions without centralizing sensitive patient information. Regulatory developments must address biases in AI algorithms and ensure compliance with privacy standards like HIPAA and GDPR to maintain trust and facilitate cross-border collaborations.

References

  1. [1]
    [PDF] Guidance for Industry: Electronic Source data in Clinical Investigations
    This FDA guidance covers electronic source data in clinical investigations, including data capture, review, and modifications.
  2. [2]
    The Use of Electronic Data Capture Tools in Clinical Trials
    Mar 9, 2009 · Electronic data capture (EDC) systems are used in all phases of clinical trials to collect, manage, and report clinical and laboratory data [1].
  3. [3]
    [PDF] Electronic Systems, Electronic Records, and Electronic Signatures in ...
    This FDA guidance covers electronic systems, records, and signatures in clinical investigations, including electronic records, systems, IT providers, digital ...
  4. [4]
    Electronic Source Data in Clinical Investigations - FDA
    Aug 24, 2018 · This guidance provides recommendations for capturing, reviewing, and retaining electronic source data in clinical investigations, used to fill ...
  5. [5]
    Electronic case report forms and electronic data capture within ...
    This review discusses electronic case report forms and electronic data capture, specifically within pharmacoepidemiology and clinical research.
  6. [6]
    Comparison of Electronic Data Capture (EDC) with the Standard ...
    Sep 23, 2011 · Given the considerable reduction in the time from data collection to database lock, EDC holds the promise to reduce research-associated costs.
  7. [7]
    Evaluating the Impact of Electronic Health Record to Electronic Data ...
    Oct 3, 2025 · The number of data entry errors was reduced by 99% (manual, 100 data points; EHR-To-EDC, 1 data point). Regarding user satisfaction, data ...
  8. [8]
    Electronic Data Capture for Registries and Clinical Trials in ...
    Phase 3 and Phase 4 clinical trials, pharmaco-vigilance studies, and safety surveillance activities are some other examples where EDC systems are used [24].
  9. [9]
    Examination of Clinical Trial Costs and Barriers for Drug Development
    Jul 24, 2014 · Another study reported that use of EDC reduced total trial costs by 9.8 percent ... savings are substantial representing 22 percent of study ...
  10. [10]
    Beginner's Guide to an Electronic Data Capture (EDC) System
    Feb 2, 2016 · An EDC system can help increase efficiency, ensure data quality, reduce the time and cost of clinical trials, and help meet regulatory ...
  11. [11]
    Benefits and challenges of electronic data capture (EDC) systems ...
    Nov 17, 2015 · EDC allows logic checks to highlight discrepancies to site staff during data entry. Data can be reported in real time, ensuring safety data are ...Missing: definition | Show results with:definition
  12. [12]
    Electronic Data Capture in Clinical Trials
    Many clinical research organizations (CROs) are approaching global electronic data capture (EDC) in an effort to improve the competence and accuracy of patient ...
  13. [13]
    Electronic Data Capture for Medical Devices: Then vs. Now
    What is the history of EDC in clinical trials? The 1980s saw the first step forward—and away from paper—in the use of remote data entry (RDE). Instead of ...Missing: origins | Show results with:origins
  14. [14]
    Meeting the Challenges of Internet-based Clinical Trials
    In the mid to late '80s, a tool called remote data entry was available which replaced double key data entry and paper case report forms (CRFs) at the clinical ...<|control11|><|separator|>
  15. [15]
    Zozus | Beyond EDC
    Mar 12, 2021 · The most common types of data managed in EDC systems included eCRF data (100%), local lab data (59.5%), and Quality of Life data (59.5%).
  16. [16]
  17. [17]
    A Brief History and Look at the Future of Electronic Data Capture
    Dec 2, 2022 · In the 1980's and 1990's, remote data entry (RDE) was introduced into the pharmaceutical industry. Personal computers were provisioned at ...Missing: origins 1980s
  18. [18]
    Medidata History Timeline
    Medidata was founded in 1999, launched Rave EDC, acquired Clinical Force, and was acquired by Dassault Systèmes. It also launched Medidata AI in 2019.
  19. [19]
    Guidance for Industry - COMPUTERIZED SYSTEMS USED IN ... - FDA
    This guidance document reflects long-standing regulations covering clinical trial records. It also addresses requirements of the Electronic Records ...
  20. [20]
    Internet, Broadband Fact Sheet - Pew Research Center
    Nov 13, 2024 · The share of U.S. adults with high-speed broadband service at home increased rapidly between 2000 and 2010. And that growth continues today: 79% ...Missing: widespread EDC
  21. [21]
    The anatomy of an electronic case report form (eCRF) - OpenClinica
    Mar 6, 2024 · An electronic case report form (eCRF) is a digital, usually web-based, questionnaire for collecting data about a study participant.
  22. [22]
    Developing Regulatory-compliant Electronic Case Report Forms for ...
    The use of electronic case report forms (CRF) to gather data in randomized clinical trials has grown to progressively replace paper-based forms.
  23. [23]
    Electronic Data Capture (EDC) Systems: What to Know
    Software-based EDC systems give clinical study managers the ability to streamline the data collection process, capture more accurate data, and enhance data ...
  24. [24]
    Why Your eTMF Needs Role-Based Access - Anju Software
    Jun 28, 2022 · Role-based access (RBAC) in eTMF protects documents, prevents unauthorized access, and helps meet regulatory demands, even with compromised ...
  25. [25]
    21 CFR Part 11 -- Electronic Records; Electronic Signatures - eCFR
    This part applies to records in electronic form that are created, modified, maintained, archived, retrieved, or transmitted, under any records requirements set ...Missing: EDC role-
  26. [26]
    Understanding 21 CFR Part 11 Compliance for EDC Systems - Klindat
    Feb 26, 2025 · EDC systems play a vital role in ensuring compliance by providing features such as electronic signature validation, audit trails, and access ...
  27. [27]
    Top Electronic Data Capture (EDC) Systems for Clinical Trials in 2025
    Jun 12, 2025 · An Electronic Data Capture (EDC) system is a web-based software platform used in clinical trials to collect, clean, and manage clinical trial data in real time.
  28. [28]
    EDC 101: What is Electronic Data Capture in Clinical Trials?
    Aug 18, 2025 · Adopting and leveraging EDC systems empowers researchers to adapt to the future of clinical trials by enhancing efficiency, data quality ...
  29. [29]
    [PDF] Guideline on computerised systems and electronic data in clinical ...
    Mar 9, 2023 · Edit checks should be validated and implementation of the individual edit checks should be controlled and documented. If edit checks are paused ...
  30. [30]
    Comprehensive Guide to Edit Checks in eCRFs for Clinical Trials
    Sep 12, 2024 · These checks ensure real-time data validation, thereby minimizing errors during data collection and streamlining data management processes. This ...Missing: backend storage
  31. [31]
    Understanding Query Management in Clinical Trials - Quanticate
    Aug 12, 2025 · Learn best practices, workflows, and new emerging trends for efficient, compliant query management in clinical trials.
  32. [32]
    Electronic Data Capture (EDC) - Merative
    Reduce programming and optimize workflows for faster first-time right clinical trial data collection using real-time data validation.
  33. [33]
    Powerful EDC Software for Clinical Trials - Prelude
    Apply cross-form edit checks and advanced and nested calculations with less manual lift. Use real-time validations to prevent errors before they happen. Cross- ...Missing: backend | Show results with:backend
  34. [34]
    Ensuring Data Security and Compliance in Clinical Trial ... - Cloudbyz
    Aug 30, 2024 · Use strong encryption standards such as AES-256 for data at rest and TLS 1.2 or higher for data in transit. Encryption Key Management ...
  35. [35]
    Automated Electronic Health Record to Electronic Data Capture ...
    Aug 4, 2023 · Automated digital transfer from EHRs to EDC systems (EHR2EDC) would enable more accurate and efficient data capture but has so far encountered ...
  36. [36]
    Data management in clinical research: An overview - PMC - NIH
    Moreover, double data entry helps in getting a cleaner database compared to a single data entry. Earlier studies have shown that double data entry ensures ...
  37. [37]
    Electronic data capture – Narrowing the gap between clinical and ...
    With EDC technology, the resolution of an electronic DCF can be obtained in 15 minutes from when the query/DCF is visible for site/investigator. This is very ...
  38. [38]
    The Upfront Cost Hurdle of EDC | Applied Clinical Trials Online
    Based on these assumptions, there are significant savings linked to reductions in the cost of query resolution, monitoring visits, and paper handling. As shown ...
  39. [39]
    How Electronic Data Capture (EDC) Can Improve Outcomes in ...
    Nov 6, 2024 · A 2023 report published by the Association of Clinical Research Organizations (ACRO) indicated that EDC systems actually managed to lower data ...
  40. [40]
    Why Scalable EDC Systems Matter in Global Pharmaceutical Trials
    A scalable EDC does more than hold forms. It supports repeatable startup, resilient operations, and reliable reporting, all while protecting data quality and ...
  41. [41]
    Quotation for an Electronic Data Capture (EDC) System - Sofpromed
    Dec 13, 2022 · License and hosting of the EDC system: Range between $14,400 and 96,000 (depending on the type of software chosen). Initial specification: ...
  42. [42]
    Implementation of electronic data capture systems: Barriers and ...
    For the sample clinical trial considered in our simulation study and our parameters estimations the EDC process decreased data collection costs for 55%.Missing: percentage | Show results with:percentage
  43. [43]
    EDC System Flexibility for Mid-Study Changes - Medidata
    Sep 6, 2022 · Learn how electronic data capture (EDC) systems must accommodate protocol amendments and other complex changes made during clinical trials.
  44. [44]
    Data security in EDC system: Challenges and Solutions - Ominext
    EDC systems are vulnerable to evolving cybersecurity threats, including ransomware, phishing, and malware attacks.
  45. [45]
    Cybersecurity threats in clinical trials - Paubox
    Mar 26, 2025 · Threats like malware, ransomware, phishing, social engineering, insider threats, advanced persistent threats (APTs), and data breaches, have continuously ...
  46. [46]
    [PDF] Guidance for Industry - Part 11, Electronic Records - FDA
    17 This guidance is intended to describe the Food and Drug Administration's (FDA's) current 18 thinking regarding the scope and application of part 11 of Title ...
  47. [47]
    [PDF] integrated addendum to ich e6(r1): guideline for good clinical practice
    Nov 9, 2016 · (a) Ensure and document that the electronic data processing system(s) conforms to the sponsor's established requirements for completeness, ...
  48. [48]
    E6(R2) Good Clinical Practice: Integrated Addendum to ICH E6(R1)
    Nov 9, 2023 · The objective of this ICH GCP guidance is to provide a unified standard for the European Union, Japan, and the United States to facilitate the ...
  49. [49]
    [PDF] Annex 11: Computerised Systems
    This document provides guidance for the interpretation of the principles and guidelines of good manufacturing practice (GMP) for medicinal products as laid down ...
  50. [50]
    EU GMP Annex 11: Computerised Systems - ECA Academy
    Supplementary guidelines to the EC-GMP Guide with specific requirements for computerized systems.
  51. [51]
    Standards - CDISC
    CDISC Data Exchange Standards facilitate the sharing of structured data across different information systems. What are CDISC Therapeutic Areas? Therapeutic Area ...Cdash · SDTM · Foundational Standards · ADaM
  52. [52]
    SDTM - CDISC
    SDTM is a standard for organizing data to streamline processes and is required for data submission to FDA and PMDA.Sdtmig · SDTMIG v3.4 · SDTMIG v3.3 · SDTM v2.1
  53. [53]
    A Basic Guide to IQ, OQ, PQ in FDA-Regulated Industries
    Feb 23, 2024 · IQ, OQ, PQ protocols are methods for demonstrating that equipment being used or installed will offer a high degree of quality assurance.
  54. [54]
    10 Benefits of EDC Electronic Data Capture for Compliance Officers
    Installation Qualification (IQ); Operational Qualification (OQ); Performance Qualification (PQ). along with a detailed validation checklist, guarantees that EDC ...
  55. [55]
    Electronic Data Capture System Validation at an Academic Institution
    A properly validated EDC provides a level of confidence to the financial study sponsor and regulatory bodies that the data at each functional level: data ...Missing: PQ | Show results with:PQ
  56. [56]
    What You Need to Know About GAMP® 5 Guide, 2nd Edition - ISPE
    GAMP® 5 Guide, 2nd Edition, seeks to meet and exceed minimum compliance expectations by encouraging the application of modern, current, good IT practices; ...
  57. [57]
    Complete GAMP 5 guide for GxP compliant computerized systems
    Jul 4, 2025 · GAMP 5 provides a risk-based approach to classifying software based on its impact on GxP and functional compliance. Category 2, associated with ...The concept behind the GAMP... · Key principles of GAMP 5... · GAMP 5 categories
  58. [58]
    [PDF] Good Clinical Data Management Practices
    Two examples applicable for clinical studies using either paper-based data collection or electronic data capture (EDC) are: (1) measurement of the number of ...
  59. [59]
    Technology Adoption in Clinical Trials: Trends & Plateaus in 2023
    Oct 31, 2023 · At the same time, we see in the chart below nearly 80 percent of clinical trials use an Electronic Data Capture (EDC) system. About 45 percent ...
  60. [60]
    Introduction to EDC Systems in Clinical Trials - Cloudbyz
    Aug 9, 2024 · Today, over 80% of clinical research utilizes EDC solutions. In this blog, we will delve into what EDC systems are, their key benefits, and why ...Missing: rate | Show results with:rate
  61. [61]
    Electronic Data Capture in Clinical Trials: Enhancing Accuracy and ...
    Jan 15, 2025 · One of the primary benefits of adopting EDC in clinical trials is the significant impact it has on data accuracy. Traditional methods of ...Missing: resistance | Show results with:resistance
  62. [62]
    Beyond the Pandemic: Impact of Decentralized Clinical Trials
    Apr 24, 2025 · Learn how decentralized clinical trials (DCTs) have moved from a temporary solution in response to the pandemic to an integral part of ...
  63. [63]
    Electronic Data Capture Systems Market Size Report, 2030
    The global electronic data capture systems market size was estimated at USD 1.25 billion in 2022 and is projected to reach USD 3.63 billion by 2030, ...
  64. [64]
    Castor's Real-World Evidence solution simplifies RWE studies
    Castor streamlines real-world evidence generation with a modern, end-to-end platform—boosting data quality, reducing costs, and accelerating insights ...
  65. [65]
    AI in Clinical Study Builds: Redefining EDC Efficiency - Medidata
    Aug 15, 2025 · Predictive Validation and Smart Edit Checks: Manual coding of each validation rule is replaced by AI algorithms that can learn from the vast ...Missing: backend | Show results with:backend
  66. [66]
    How Using Digital Tools Accelerates Your Clinical Trials in 2024 ...
    Nov 27, 2024 · Speed to Market: The adoption of EDC solutions has been shown to lessen trial timelines by up to 20% (Clinical Research News, 2024). · Real-Time ...Missing: percentage | Show results with:percentage
  67. [67]
    EDC (Electronic Data Capture) System Market Key Insights, Trends ...
    Aug 15, 2025 · Asia-Pacific has become a key region for EDC system adoption, driven by the rapid expansion of the healthcare sector and increasing clinical ...
  68. [68]
    Cloud-Based Clinical Trial Market Size, Report by 2034
    Jul 11, 2025 · North America dominated the cloud-based clinical trial market, holding a 49.50% share in 2024. Asia Pacific is expected to expand at the fastest ...
  69. [69]
    electronic data capture systems market size & share analysis
    Oct 24, 2025 · The Electronic Data Capture Systems Market is expected to reach USD 1.86 billion in 2025 and grow at a CAGR of 12.02% to reach USD 3.28 ...
  70. [70]
  71. [71]
  72. [72]
    Oracle Life Sciences Positioned as a Leader in the Everest Group ...
    Oct 24, 2024 · Oracle Life Sciences has been named a 'Leader' in the Everest Group Electronic Data Capture (EDC) Products PEAK Matrix Assessment 2024.Missing: position | Show results with:position
  73. [73]
    Veeva Vault EDC Surpasses 1000 Study Start Milestone
    Veeva Vault EDC simplifies complex data management for faster study builds and streamlined processes.
  74. [74]
    Electronic Data Capture » EDC for Clinical Trials. - OpenClinica
    OpenClinica's electronic data capture (EDC) system accelerates clinical trial data management with automation, compliance, and scalability.
  75. [75]
    EMR to EDC Solution - IQVIA
    Transforming real world data into evidence. Integrate EMR data into your study workflow through our EMR to EDC solution. Contact us. Solutions Real World ...Missing: mobile | Show results with:mobile
  76. [76]
    Electronic Data Capture for Advanced Clinical Studies | Veeva
    The EDC for Everyone. Electronic Data Capture (EDC) provides an end-to-end environment to collect, review, and process site-reported patient trial data.Missing: backend storage edit
  77. [77]
    EHR-to-EDC Integration Platforms Market Research Report 2033
    The market is poised for robust growth, projected to expand at a CAGR of 13.8% from 2025 to 2033. By the end of 2033, the EHR-to-EDC Integration Platforms ...
  78. [78]
    Electronic Data Capture (EDC) Software for Clinical Trials
    Castor's electronic data capture (EDC) makes it easier to capture your trial data and integrate it seamlessly with other data in your clinical trial ecosystem.Missing: niche small
  79. [79]
    Clinical Solutions - MedTech - IQVIA
    Comprehensive and flexible EDC system. Hosted on Microsoft Azure, collects, stores and preserves health data in accordance with applicable local and global ...
  80. [80]
    Top EDC Software Solutions for Streamlining Clinical Trials in 2025
    Nov 18, 2024 · This article delves into the essential function of EDC software, highlights leading solutions for 2025, and explores the impact of technology on clinical ...
  81. [81]
    The New Era of Medical Monitoring | Ergomed CRO
    AI is transforming clinical trial oversight by automating data reconciliation, anomaly detection, and safety signal analysis, enabling medical monitors to focus ...
  82. [82]
    AI Powered Orchestration | Emmes Group
    50–70% fewer manual queries through real-time anomaly detection and intelligent query management. 30–50% reduction in last-patient-visit to database lock time.
  83. [83]
    Using Behavioral AI to Predict and Prevent Clinical Trial Dropouts
    Oct 21, 2025 · Demolle noted that 25–30% of participants drop out, and one-third of these are due to behavioral factors like anxiety or loss of motivation. Yet ...
  84. [84]
    Blockchain and EDC: Securing Clinical Trial Data
    Feb 16, 2024 · Blockchain can simplify the regulatory compliance process by providing a transparent and auditable record of data handling. It decreases the ...
  85. [85]
    An artificial intelligence and blockchain technology-based data ...
    Mar 30, 2025 · Traditional electronic data collection (EDC) systems for clinical trials primarily focus on data entry, validation, and compliance monitoring.Missing: capture | Show results with:capture
  86. [86]
    Electronic Data Capture (EDC) in 2025 - BizNET - Sarjen Systems
    Feb 14, 2025 · Blockchain for Data Security: AI bots and blockchain technology will work together to ensure secure, tamper-proof clinical trial records.
  87. [87]
    DCT Platforms 2025: Integration Guide for Clinical Ops - Castor EDC
    Decentralized clinical trials (DCTs) leverage digital technologies and alternative care delivery methods to bring trial activities closer to participants.
  88. [88]
    The Importance of Mobile Technology and Wearables in Clinical ...
    Wearable technology in clinical trials includes hardware such as sports watches, chest straps, patches, monitoring devices, and wearable sensors like pulse ...Missing: IoT EDC
  89. [89]
    Highly-Rated eCOA / ePRO Solutions for Clinical Trials - Castor EDC
    Castor eCOA / ePRO delivers rapid, compliant, and scalable patient-reported data capture—whether you're running traditional, hybrid, or fully decentralized ...<|separator|>
  90. [90]
    ePRO in Clinical Research: Debunking Common Objections
    Sep 4, 2024 · ePRO systems can limit questionnaire access based on IP addresses, which is useful for restricting access to specific geographic regions.<|control11|><|separator|>
  91. [91]
    Electronic patient-reported outcomes as digital therapeutics for ... - NIH
    Nov 16, 2024 · This review delineates the advantages and challenges of ePROs according to their history and proposes the prospects of ePRO.
  92. [92]
    [PDF] Digital Health Technologies for Remote Data Acquisition in Clinical ...
    This FDA guidance covers digital health technologies for remote data acquisition in clinical investigations, including selection, description, verification, ...Missing: EHR 2030
  93. [93]
    [PDF] eSource: The Evolution of Clinical Trial Data Capture - Medidata
    We divide eSource into two broad categories - Direct Capture and Automated Capture. TOPIC GUIDE. ESOURCE: THE EVOLUTION OF CLINICAL TRIAL DATA CAPTURE.
  94. [94]
    Ecoa Esource and Clinical Trials Market By Share, Size and Growth ...
    The global ECoa eSource and clinical trials market has grown steadily in recent years and is predicted to increase at an 8.30% CAGR between 2023 and 2030.
  95. [95]
    How Modern EDC Systems Are Becoming Clinical Intelligence Hubs
    EDC platforms are no longer just repositories for data—they're becoming dynamic clinical intelligence hubs that drive smarter, faster decisions ...Ai/ml Integration: Turning... · Predictive Analytics... · Real-Time Monitoring...<|control11|><|separator|>
  96. [96]
    The Future of Clinical Trials with AI and Decentralized, Hybrid and ...
    Sep 25, 2025 · Through simulations and predictive analytics, researchers can refine trial parameters, ultimately leading to more adaptable and meaningful ...Missing: adaptive | Show results with:adaptive
  97. [97]
    Decentralized Clinical Trials Market Analysis & Forecast, 2034
    The global decentralized clinical trials market was valued at USD 8.6 billion in 2024. The market is expected to grow from USD 9.7 billion in 2025 to USD ...Missing: predictions | Show results with:predictions
  98. [98]
    Future Trends in Clinical Trial Staffing: What to Expect by 2030
    Mar 27, 2025 · Over 61% of sites now use eSource systems (up from 38% pre-pandemic), redirecting human expertise toward complex patient engagement, protocol ...
  99. [99]
    Advance environmental sustainability in clinical trials using AWS
    Nov 1, 2024 · Decentralized clinical trials reduce emissions compared to regular clinical trials by eliminating the need for travel and physical ...Missing: green EDC
  100. [100]
    Clinical Trial Technologies for Improving Equity and Inclusion in ...
    Apr 12, 2023 · Breakthrough technologies in clinical trials include synthetic biologies, digital twins, big data analytics, wearable devices and sensors, ...
  101. [101]
    Ethical and regulatory challenges of AI technologies in healthcare
    Feb 15, 2024 · This article delves deep into the critical ethical and regulatory concerns entangled with the deployment of AI systems in clinical practice.Missing: EDC | Show results with:EDC
  102. [102]
    The Promises and Predicaments of Federated Learning in Healthcare
    In this paper, we have discussed three FL challenges, namely: privacy of the model exchange, ethical perspectives, and legal considerations.Missing: trials EDC